Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study

References

• Nugent D, McMillan R, Nichol JL, Slichter SJ, Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. British J Haematol 2009;146(6):585–596. doi:https://doi.org/10.1111/j.1365-2141.2009.07717.x.
   PubMed Web of Science ®Google Scholar
• Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 2005;56:425–442. doi:https://doi.org/10.1146/annurev.med.56.082103.104644.
   PubMed Web of Science ®Google Scholar
• Arnold DM. Bleeding complications in immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2015;2015:237–242. doi:https://doi.org/10.1182/asheducation-2015.1.237.
   PubMed Web of Science ®Google Scholar
• Neunert C, Noroozi N, Norman G, Buchanan GR, Goy J, Nazi I, Kelton JG, Arnold DM, Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost 2015;13(3):457–464. doi:https://doi.org/10.1111/jth.12813.
   PubMed Web of Science ®Google Scholar
• Fogarty PF, Segal JB, The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol 2007;14(5):515–519. doi:https://doi.org/10.1097/MOH.0b013e3282ab98c7.
   PubMed Web of Science ®Google Scholar
• Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L, Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood 2014;124(22):3308–3315. doi:https://doi.org/10.1182/blood-2014-05-578336.
   PubMed Web of Science ®Google Scholar
• Schoonen WM, Kucera G, Coalson J, Li L, Rutstein M, Mowat F, Fryzek J, Kaye JA, Epidemiology of immune thrombocytopenic purpura in the general practice research database. Br J Haematol 2009;145(2):235–244. doi:https://doi.org/10.1111/j.1365-2141.2009.07615.x.
   PubMed Web of Science ®Google Scholar
• Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M, Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol 2011;93(3):329–335. doi:https://doi.org/10.1007/s12185-011-0791-1.
   PubMed Web of Science ®Google Scholar
• Lee JY, Lee JH, Lee H, Kang B, Kim JW, Kim SH, Lee JO, Kim JW, Kim YJ, Lee KW, et al. Epidemiology and management of primary immune thrombocytopenia: a nationwide population-based study in Korea. Thromb Res 2017;155:86–91. doi:https://doi.org/10.1016/j.thromres.2017.05.010.
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA, American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117(16):4190–4207. doi:https://doi.org/10.1182/blood-2010-08-302984.
   PubMed Web of Science ®Google Scholar
• Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB, Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377(9763):393–402. doi:https://doi.org/10.1016/S0140-6736(10)60959-2.
   PubMed Web of Science ®Google Scholar
• Liu XG, Bai XC, Chen FP, Cheng YF, Dai KS, Fang MY, Feng JM, Gong YP, Guo T, Guo XH, et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia. Int J Hematol. 2018;107(6):615–623. doi:https://doi.org/10.1007/s12185-018-2445-z
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. The N Engl J Med. 2007;357(22):2237–2247. doi:https://doi.org/10.1056/NEJMoa073275
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9664):641–648. doi:https://doi.org/10.1016/S0140-6736(09)60402-5
   PubMed Web of Science ®Google Scholar
• Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A, EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121(3):537–545. doi:https://doi.org/10.1182/blood-2012-04-425512.
   PubMed Web of Science ®Google Scholar
• Katsutani S, Tomiyama Y, Kimura A, Miyakawa Y, Okamoto S, Okoshi Y, Ninomiya H, Kosugi H, Ishii K, Ikeda Y, et al. Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study. Int J Hematol. 2013;98(3):323–330. doi:https://doi.org/10.1007/s12185-013-1401-1
   PubMed Web of Science ®Google Scholar
• Tomiyama Y, Miyakawa Y, Okamoto S, Katsutani S, Kimura A, Okoshi Y, Ninomiya H, Kosugi H, Nomura S, Ozaki K, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012;10(5):799–806. doi:https://doi.org/10.1111/j.1538-7836.2012.04695.x
   PubMed Web of Science ®Google Scholar
• Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D, Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol 2011;51(6):842–856. doi:https://doi.org/10.1177/0091270010375427.
   PubMed Web of Science ®Google Scholar
• Yang R, Li J, Jin J, Huang M, Yu Z, Xu X, Zhang X, Hou M, Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Br J Haematol 2017;176(1):101–110. doi:https://doi.org/10.1111/bjh.14380.
   PubMed Web of Science ®Google Scholar
• Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM, Selective validation of the WHO bleeding scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin 2012;28(1):79–87. doi:https://doi.org/10.1185/03007995.2011.644849.
   PubMed Web of Science ®Google Scholar
• Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB, Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 2017;130(23):2527–2536. doi:https://doi.org/10.1182/blood-2017-04-748707.
   PubMed Web of Science ®Google Scholar
• Wong RSM, Bussel JB, Saleh MN, Khelif A, Meddeb B, El-Ali A, Quebe-Fehling E, Salama A, Efficacy of eltrombopag in adult East Asian and non-East Asian patients with chronic immune thrombocytopenia (cITP): results from the extend study. Blood 2016;128(22):4930. doi:https://doi.org/10.1182/blood.V128.22.4930.4930.
   Google Scholar
• Saleh MN, Bussel JB, Wong RSM, Meddeb B, Salama A, El-Ali A, Quebe-Fehling E, Khelif A, Hepatobiliary and thromboembolic events during long-term EXTENDed treatment with eltrombopag in adult patients with chronic immune thrombocytopenia (ITP). Blood 2016;128(22):1368. doi:https://doi.org/10.1182/blood.V128.22.1368.1368.
   Web of Science ®Google Scholar